| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| NF-E2-Related Factor 2 | 26 | 2022 | 110 | 8.800 |
Why?
|
| Autophagy | 16 | 2022 | 208 | 4.000 |
Why?
|
| Myocytes, Cardiac | 17 | 2020 | 442 | 3.970 |
Why?
|
| Muscle, Smooth, Vascular | 14 | 2020 | 317 | 2.600 |
Why?
|
| Myocardium | 14 | 2020 | 1204 | 2.580 |
Why?
|
| Myocytes, Smooth Muscle | 9 | 2022 | 144 | 2.350 |
Why?
|
| Cardiomegaly | 7 | 2017 | 213 | 2.300 |
Why?
|
| Oleanolic Acid | 5 | 2016 | 7 | 2.270 |
Why?
|
| Oxidative Stress | 20 | 2020 | 718 | 2.070 |
Why?
|
| Panax | 5 | 2020 | 31 | 1.790 |
Why?
|
| Antioxidants | 5 | 2022 | 304 | 1.660 |
Why?
|
| Signal Transduction | 25 | 2022 | 2689 | 1.630 |
Why?
|
| Ventricular Remodeling | 6 | 2020 | 318 | 1.590 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2015 | 194 | 1.550 |
Why?
|
| Macrophages | 7 | 2021 | 647 | 1.530 |
Why?
|
| Ubiquitin Thiolesterase | 4 | 2015 | 24 | 1.410 |
Why?
|
| Up-Regulation | 14 | 2020 | 682 | 1.410 |
Why?
|
| Plant Extracts | 6 | 2020 | 122 | 1.410 |
Why?
|
| Animals | 62 | 2021 | 20880 | 1.330 |
Why?
|
| Deubiquitinating Enzyme CYLD | 6 | 2020 | 7 | 1.270 |
Why?
|
| Endothelial Cells | 4 | 2020 | 384 | 1.230 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2016 | 234 | 1.220 |
Why?
|
| Rats | 29 | 2020 | 5300 | 1.200 |
Why?
|
| Mice | 36 | 2021 | 8474 | 1.180 |
Why?
|
| Cardiomyopathies | 5 | 2020 | 167 | 1.180 |
Why?
|
| Diabetic Cardiomyopathies | 4 | 2020 | 17 | 1.120 |
Why?
|
| Mice, Knockout | 18 | 2020 | 1692 | 1.030 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 5 | 2015 | 175 | 1.020 |
Why?
|
| Cell Proliferation | 8 | 2020 | 1174 | 1.000 |
Why?
|
| Fibroblasts | 5 | 2020 | 902 | 0.960 |
Why?
|
| Cells, Cultured | 19 | 2022 | 2673 | 0.940 |
Why?
|
| Lysosomes | 5 | 2020 | 136 | 0.930 |
Why?
|
| Pressure | 3 | 2020 | 252 | 0.910 |
Why?
|
| Cysteine Endopeptidases | 2 | 2015 | 39 | 0.910 |
Why?
|
| Autophagy-Related Protein 7 | 2 | 2020 | 3 | 0.900 |
Why?
|
| Neointima | 2 | 2020 | 7 | 0.840 |
Why?
|
| Down-Regulation | 2 | 2015 | 447 | 0.790 |
Why?
|
| Aorta | 5 | 2015 | 316 | 0.730 |
Why?
|
| Jugular Veins | 1 | 2020 | 37 | 0.720 |
Why?
|
| Surgical Wound | 1 | 2020 | 8 | 0.710 |
Why?
|
| Glomerulonephritis, IGA | 2 | 2009 | 12 | 0.700 |
Why?
|
| Diynes | 2 | 2020 | 6 | 0.700 |
Why?
|
| Fatty Alcohols | 2 | 2020 | 14 | 0.690 |
Why?
|
| Renin-Angiotensin System | 2 | 2019 | 78 | 0.680 |
Why?
|
| Cell Line | 11 | 2021 | 1752 | 0.680 |
Why?
|
| Wound Healing | 2 | 2020 | 260 | 0.650 |
Why?
|
| Blood Pressure | 4 | 2013 | 1449 | 0.620 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2015 | 201 | 0.560 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2012 | 626 | 0.550 |
Why?
|
| Renal Dialysis | 3 | 2013 | 174 | 0.550 |
Why?
|
| Angiotensin II | 9 | 2019 | 220 | 0.540 |
Why?
|
| Body Water | 2 | 2013 | 35 | 0.530 |
Why?
|
| Mice, Inbred C57BL | 12 | 2021 | 2791 | 0.530 |
Why?
|
| Male | 36 | 2021 | 37283 | 0.530 |
Why?
|
| Cardiovascular Diseases | 3 | 2019 | 938 | 0.520 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 88 | 0.520 |
Why?
|
| Multipotent Stem Cells | 1 | 2015 | 6 | 0.520 |
Why?
|
| Exosomes | 1 | 2015 | 44 | 0.510 |
Why?
|
| Ventricular Pressure | 1 | 2015 | 82 | 0.510 |
Why?
|
| Cardiovascular Agents | 1 | 2016 | 82 | 0.510 |
Why?
|
| Ubiquitin-Specific Proteases | 1 | 2015 | 1 | 0.510 |
Why?
|
| Drug Discovery | 1 | 2016 | 94 | 0.490 |
Why?
|
| NF-kappa B | 7 | 2014 | 432 | 0.490 |
Why?
|
| Inflammation Mediators | 2 | 2021 | 244 | 0.490 |
Why?
|
| Ubiquitinated Proteins | 1 | 2014 | 1 | 0.480 |
Why?
|
| Heart | 4 | 2018 | 850 | 0.480 |
Why?
|
| Cardiovascular System | 1 | 2015 | 85 | 0.470 |
Why?
|
| Insulin-Secreting Cells | 1 | 2014 | 41 | 0.470 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 97 | 0.460 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2011 | 38 | 0.450 |
Why?
|
| Electric Impedance | 2 | 2013 | 131 | 0.450 |
Why?
|
| Heart Failure | 3 | 2017 | 1179 | 0.440 |
Why?
|
| Doxorubicin | 1 | 2014 | 231 | 0.430 |
Why?
|
| Insulin Resistance | 3 | 2011 | 241 | 0.430 |
Why?
|
| Sodium | 1 | 2013 | 161 | 0.430 |
Why?
|
| Recombinant Proteins | 6 | 2014 | 742 | 0.420 |
Why?
|
| Arteritis | 1 | 2012 | 4 | 0.420 |
Why?
|
| Spike Glycoprotein, Coronavirus | 2 | 2022 | 20 | 0.410 |
Why?
|
| Hypertension | 3 | 2013 | 1533 | 0.410 |
Why?
|
| Gene Expression Regulation | 11 | 2018 | 1293 | 0.390 |
Why?
|
| Rats, Sprague-Dawley | 12 | 2017 | 2083 | 0.390 |
Why?
|
| Ubiquitination | 3 | 2020 | 85 | 0.380 |
Why?
|
| Chronic Disease | 1 | 2016 | 1329 | 0.380 |
Why?
|
| Linoleic Acids | 2 | 2008 | 12 | 0.380 |
Why?
|
| Body Weight | 1 | 2013 | 554 | 0.380 |
Why?
|
| Nitro Compounds | 2 | 2008 | 11 | 0.380 |
Why?
|
| Humans | 34 | 2022 | 68549 | 0.380 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 161 | 0.380 |
Why?
|
| PPAR gamma | 3 | 2021 | 95 | 0.360 |
Why?
|
| STAT1 Transcription Factor | 2 | 2019 | 35 | 0.360 |
Why?
|
| Nephritis, Interstitial | 1 | 2009 | 14 | 0.350 |
Why?
|
| Isothiocyanates | 3 | 2018 | 10 | 0.340 |
Why?
|
| STAT Transcription Factors | 1 | 2009 | 13 | 0.340 |
Why?
|
| Kidney Tubules | 1 | 2009 | 80 | 0.340 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2020 | 24 | 0.330 |
Why?
|
| Macrophage Activation | 1 | 2009 | 75 | 0.330 |
Why?
|
| Dual Specificity Phosphatase 1 | 2 | 2008 | 22 | 0.330 |
Why?
|
| Mice, Transgenic | 5 | 2020 | 1033 | 0.330 |
Why?
|
| Disease Models, Animal | 10 | 2020 | 2550 | 0.330 |
Why?
|
| Diabetes Mellitus | 2 | 2013 | 694 | 0.320 |
Why?
|
| Alkenes | 1 | 2008 | 7 | 0.320 |
Why?
|
| Hypertrophy | 3 | 2015 | 89 | 0.320 |
Why?
|
| Apoptosis | 6 | 2022 | 1641 | 0.320 |
Why?
|
| Cell Movement | 4 | 2020 | 630 | 0.310 |
Why?
|
| Animals, Newborn | 3 | 2015 | 396 | 0.310 |
Why?
|
| Metallothionein | 2 | 2018 | 20 | 0.310 |
Why?
|
| Insulin | 2 | 2011 | 617 | 0.310 |
Why?
|
| Gene Knockdown Techniques | 3 | 2015 | 196 | 0.300 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 236 | 0.300 |
Why?
|
| Glucose | 3 | 2014 | 307 | 0.290 |
Why?
|
| Hydrogen Peroxide | 3 | 2014 | 168 | 0.290 |
Why?
|
| Hypoxia | 2 | 2018 | 169 | 0.290 |
Why?
|
| Kidney Diseases | 1 | 2009 | 307 | 0.280 |
Why?
|
| Hyperplasia | 2 | 2020 | 89 | 0.280 |
Why?
|
| Reactive Oxygen Species | 4 | 2015 | 499 | 0.280 |
Why?
|
| MAP Kinase Signaling System | 6 | 2013 | 247 | 0.280 |
Why?
|
| Pichia | 3 | 2014 | 3 | 0.270 |
Why?
|
| Lipopolysaccharides | 1 | 2008 | 455 | 0.270 |
Why?
|
| STAT3 Transcription Factor | 3 | 2019 | 86 | 0.260 |
Why?
|
| Fatty Acids | 1 | 2006 | 222 | 0.260 |
Why?
|
| Phosphorylation | 5 | 2014 | 1200 | 0.260 |
Why?
|
| Arteries | 1 | 2005 | 108 | 0.240 |
Why?
|
| Cardiotonic Agents | 2 | 2018 | 71 | 0.240 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2015 | 134 | 0.230 |
Why?
|
| Fibronectins | 2 | 2014 | 130 | 0.230 |
Why?
|
| Ubiquitin | 3 | 2020 | 74 | 0.230 |
Why?
|
| Proteins | 1 | 2007 | 473 | 0.220 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2020 | 32 | 0.220 |
Why?
|
| Fibrosis | 3 | 2014 | 371 | 0.220 |
Why?
|
| GA-Binding Protein Transcription Factor | 1 | 2022 | 2 | 0.220 |
Why?
|
| Diabetes Mellitus, Experimental | 3 | 2015 | 195 | 0.210 |
Why?
|
| Necrosis | 3 | 2022 | 239 | 0.210 |
Why?
|
| Blotting, Western | 3 | 2011 | 954 | 0.210 |
Why?
|
| HEK293 Cells | 3 | 2022 | 326 | 0.200 |
Why?
|
| RNA, Small Interfering | 5 | 2020 | 434 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 2 | 2018 | 13 | 0.190 |
Why?
|
| RNA, Messenger | 6 | 2017 | 1663 | 0.190 |
Why?
|
| Lipid Metabolism | 1 | 2022 | 186 | 0.190 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 2 | 2018 | 57 | 0.190 |
Why?
|
| Models, Biological | 2 | 2015 | 981 | 0.190 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 4 | 2004 | 95 | 0.190 |
Why?
|
| Myoblasts | 1 | 2020 | 22 | 0.190 |
Why?
|
| Vacuoles | 1 | 2020 | 10 | 0.180 |
Why?
|
| Calcineurin | 1 | 2020 | 13 | 0.180 |
Why?
|
| Chemokine CCL2 | 3 | 2014 | 101 | 0.180 |
Why?
|
| Transcription, Genetic | 3 | 2013 | 562 | 0.180 |
Why?
|
| Genes, ras | 1 | 2020 | 46 | 0.180 |
Why?
|
| Endothelium, Vascular | 2 | 2020 | 371 | 0.180 |
Why?
|
| Vascular Remodeling | 1 | 2020 | 34 | 0.180 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2020 | 69 | 0.180 |
Why?
|
| Cytokines | 2 | 2015 | 866 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2018 | 331 | 0.180 |
Why?
|
| Paracrine Communication | 1 | 2020 | 31 | 0.180 |
Why?
|
| Colitis, Ulcerative | 1 | 2020 | 53 | 0.180 |
Why?
|
| Cell Nucleus | 2 | 2012 | 305 | 0.180 |
Why?
|
| Lysine | 1 | 2020 | 96 | 0.180 |
Why?
|
| Culture Media, Conditioned | 1 | 2020 | 78 | 0.180 |
Why?
|
| Nitric Oxide | 4 | 2008 | 382 | 0.180 |
Why?
|
| Phytotherapy | 2 | 2020 | 53 | 0.180 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 56 | 0.180 |
Why?
|
| Monocytes | 2 | 2012 | 210 | 0.180 |
Why?
|
| Skin | 2 | 2020 | 451 | 0.170 |
Why?
|
| Cell Adhesion | 2 | 2012 | 324 | 0.170 |
Why?
|
| Keratinocytes | 1 | 2020 | 68 | 0.170 |
Why?
|
| Cellular Senescence | 1 | 2020 | 112 | 0.170 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2019 | 38 | 0.170 |
Why?
|
| Cell Communication | 1 | 2020 | 116 | 0.170 |
Why?
|
| Mesoderm | 1 | 2020 | 231 | 0.170 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2020 | 140 | 0.170 |
Why?
|
| Tetrazoles | 3 | 2004 | 160 | 0.170 |
Why?
|
| Gene Silencing | 2 | 2020 | 137 | 0.170 |
Why?
|
| Imidazoles | 5 | 2013 | 175 | 0.160 |
Why?
|
| Neovascularization, Physiologic | 1 | 2020 | 164 | 0.160 |
Why?
|
| Immunohistochemistry | 3 | 2011 | 1174 | 0.160 |
Why?
|
| Regeneration | 1 | 2019 | 105 | 0.160 |
Why?
|
| Rats, Wistar | 2 | 2019 | 371 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2021 | 154 | 0.160 |
Why?
|
| Proteasome Inhibitors | 2 | 2020 | 29 | 0.150 |
Why?
|
| Stem Cells | 1 | 2019 | 248 | 0.150 |
Why?
|
| Cell Differentiation | 2 | 2015 | 1034 | 0.150 |
Why?
|
| Gene Expression | 3 | 2014 | 770 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2010 | 1745 | 0.150 |
Why?
|
| Proteolysis | 2 | 2014 | 97 | 0.140 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2019 | 201 | 0.140 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2007 | 284 | 0.140 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2016 | 3 | 0.140 |
Why?
|
| I-kappa B Proteins | 2 | 2007 | 47 | 0.130 |
Why?
|
| Amiloride | 1 | 2015 | 22 | 0.130 |
Why?
|
| Benzylidene Compounds | 1 | 2015 | 16 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2015 | 331 | 0.130 |
Why?
|
| Protein Array Analysis | 1 | 2015 | 32 | 0.130 |
Why?
|
| Quality Control | 1 | 2016 | 81 | 0.130 |
Why?
|
| Plants, Medicinal | 1 | 2016 | 43 | 0.130 |
Why?
|
| Ultrasonography | 2 | 2015 | 453 | 0.130 |
Why?
|
| Aniline Compounds | 1 | 2015 | 52 | 0.130 |
Why?
|
| Unfolded Protein Response | 1 | 2016 | 70 | 0.130 |
Why?
|
| ras Proteins | 2 | 2007 | 102 | 0.130 |
Why?
|
| Biological Assay | 1 | 2016 | 88 | 0.130 |
Why?
|
| Transcription Factor AP-1 | 1 | 2015 | 61 | 0.130 |
Why?
|
| Female | 7 | 2020 | 38021 | 0.130 |
Why?
|
| Cell Survival | 2 | 2017 | 901 | 0.130 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 807 | 0.120 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 89 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2015 | 122 | 0.120 |
Why?
|
| Structure-Activity Relationship | 1 | 2016 | 420 | 0.120 |
Why?
|
| Azetidinecarboxylic Acid | 2 | 2005 | 2 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 90 | 0.120 |
Why?
|
| Dihydropyridines | 2 | 2005 | 13 | 0.120 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2014 | 45 | 0.120 |
Why?
|
| Molecular Structure | 1 | 2016 | 397 | 0.120 |
Why?
|
| Constriction | 2 | 2012 | 37 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2015 | 250 | 0.120 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2014 | 11 | 0.120 |
Why?
|
| Sincalide | 1 | 2014 | 12 | 0.120 |
Why?
|
| Valine | 2 | 2004 | 43 | 0.120 |
Why?
|
| Cardiotoxicity | 1 | 2014 | 12 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2014 | 25 | 0.120 |
Why?
|
| Protein Aggregation, Pathological | 1 | 2014 | 13 | 0.120 |
Why?
|
| Chemokine CCL4 | 1 | 2014 | 6 | 0.120 |
Why?
|
| Lymphokines | 1 | 2014 | 49 | 0.120 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2014 | 45 | 0.120 |
Why?
|
| Dialysis Solutions | 1 | 2013 | 5 | 0.120 |
Why?
|
| Lactose | 1 | 2013 | 7 | 0.120 |
Why?
|
| Pasteurization | 1 | 2013 | 3 | 0.120 |
Why?
|
| Interleukin-4 | 1 | 2014 | 69 | 0.120 |
Why?
|
| Pyrococcus furiosus | 1 | 2013 | 5 | 0.120 |
Why?
|
| beta-Glucosidase | 1 | 2013 | 7 | 0.120 |
Why?
|
| Stress, Physiological | 1 | 2015 | 215 | 0.120 |
Why?
|
| Molecular Chaperones | 1 | 2014 | 81 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2014 | 114 | 0.110 |
Why?
|
| Milk | 1 | 2013 | 43 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 2 | 2005 | 183 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2012 | 82 | 0.110 |
Why?
|
| Proteomics | 1 | 2015 | 246 | 0.110 |
Why?
|
| Cell Cycle | 1 | 2015 | 312 | 0.110 |
Why?
|
| Cations, Monovalent | 1 | 2013 | 4 | 0.110 |
Why?
|
| Hemodialysis Solutions | 1 | 2013 | 3 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2015 | 714 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 322 | 0.110 |
Why?
|
| Thiocyanates | 1 | 2013 | 5 | 0.110 |
Why?
|
| Adipocytes | 1 | 2013 | 88 | 0.110 |
Why?
|
| Blood Volume | 1 | 2013 | 47 | 0.110 |
Why?
|
| Heart Ventricles | 1 | 2017 | 738 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2014 | 489 | 0.110 |
Why?
|
| Leupeptins | 1 | 2012 | 23 | 0.110 |
Why?
|
| Protein Transport | 3 | 2009 | 280 | 0.110 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2003 | 56 | 0.110 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2004 | 134 | 0.110 |
Why?
|
| Sulfoxides | 3 | 2018 | 16 | 0.110 |
Why?
|
| Janus Kinase 2 | 1 | 2012 | 40 | 0.110 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2012 | 55 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2007 | 216 | 0.110 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2012 | 73 | 0.110 |
Why?
|
| Cytophagocytosis | 1 | 2012 | 1 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 290 | 0.100 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2012 | 6 | 0.100 |
Why?
|
| Cholesterol | 1 | 2013 | 331 | 0.100 |
Why?
|
| Mice, Inbred ICR | 1 | 2012 | 44 | 0.100 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2012 | 21 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2013 | 226 | 0.100 |
Why?
|
| RNA Interference | 2 | 2010 | 266 | 0.100 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 411 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 307 | 0.100 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 219 | 0.100 |
Why?
|
| Erythrocytes | 1 | 2012 | 137 | 0.100 |
Why?
|
| Middle Aged | 4 | 2014 | 21119 | 0.100 |
Why?
|
| Receptor, Angiotensin, Type 1 | 5 | 2019 | 80 | 0.100 |
Why?
|
| Feedback, Physiological | 1 | 2011 | 38 | 0.090 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2012 | 125 | 0.090 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 43 | 0.090 |
Why?
|
| Phenols | 1 | 2011 | 73 | 0.090 |
Why?
|
| Extracellular Fluid | 1 | 2010 | 29 | 0.090 |
Why?
|
| Vasoconstrictor Agents | 1 | 2011 | 107 | 0.090 |
Why?
|
| Oxidants | 1 | 2010 | 48 | 0.090 |
Why?
|
| Cullin Proteins | 1 | 2009 | 14 | 0.090 |
Why?
|
| Enzyme Activation | 2 | 2009 | 791 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 710 | 0.090 |
Why?
|
| Vasculitis | 1 | 2009 | 33 | 0.090 |
Why?
|
| Reactive Nitrogen Species | 1 | 2009 | 32 | 0.090 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2009 | 33 | 0.090 |
Why?
|
| Body Composition | 1 | 2010 | 119 | 0.090 |
Why?
|
| Protein Stability | 1 | 2009 | 89 | 0.090 |
Why?
|
| Calcium | 1 | 2013 | 929 | 0.090 |
Why?
|
| Brain | 1 | 2020 | 2176 | 0.090 |
Why?
|
| Muscle Proteins | 3 | 2007 | 94 | 0.080 |
Why?
|
| Transfection | 3 | 2007 | 782 | 0.080 |
Why?
|
| Coronary Vessels | 1 | 2012 | 313 | 0.080 |
Why?
|
| Proteinuria | 1 | 2009 | 136 | 0.080 |
Why?
|
| Cell Death | 1 | 2010 | 329 | 0.080 |
Why?
|
| Palmitic Acid | 2 | 2022 | 51 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 1 | 2009 | 108 | 0.080 |
Why?
|
| Leg | 1 | 2010 | 191 | 0.080 |
Why?
|
| Administration, Oral | 1 | 2010 | 411 | 0.080 |
Why?
|
| Protein Biosynthesis | 1 | 2009 | 181 | 0.080 |
Why?
|
| DNA Primers | 1 | 2009 | 302 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 244 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2009 | 274 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2013 | 3703 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2011 | 1040 | 0.080 |
Why?
|
| Oleic Acids | 1 | 2008 | 40 | 0.080 |
Why?
|
| Reference Values | 1 | 2009 | 579 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2012 | 529 | 0.080 |
Why?
|
| Random Allocation | 1 | 2009 | 442 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 492 | 0.080 |
Why?
|
| Genes, Reporter | 2 | 2005 | 191 | 0.080 |
Why?
|
| Sulfhydryl Compounds | 1 | 2008 | 73 | 0.080 |
Why?
|
| Embryonic Stem Cells | 1 | 2007 | 40 | 0.080 |
Why?
|
| Homeostasis | 1 | 2009 | 291 | 0.080 |
Why?
|
| Base Sequence | 1 | 2009 | 1015 | 0.070 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2007 | 10 | 0.070 |
Why?
|
| Cell Lineage | 1 | 2007 | 146 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2010 | 365 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 189 | 0.070 |
Why?
|
| Time Factors | 3 | 2010 | 4655 | 0.070 |
Why?
|
| Heme Oxygenase (Decyclizing) | 1 | 2006 | 11 | 0.070 |
Why?
|
| Carrier Proteins | 1 | 2009 | 597 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2018 | 223 | 0.070 |
Why?
|
| Nitrogen | 1 | 2006 | 57 | 0.070 |
Why?
|
| Hemodynamics | 1 | 2009 | 705 | 0.070 |
Why?
|
| Inflammation | 3 | 2008 | 1030 | 0.070 |
Why?
|
| Logistic Models | 1 | 2009 | 1419 | 0.070 |
Why?
|
| Rats, Inbred WKY | 1 | 2005 | 48 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2006 | 217 | 0.060 |
Why?
|
| Rats, Inbred SHR | 1 | 2005 | 95 | 0.060 |
Why?
|
| Adult | 3 | 2013 | 21379 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2005 | 189 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2005 | 196 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 848 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 1753 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 4843 | 0.060 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2004 | 29 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2005 | 295 | 0.060 |
Why?
|
| Butadienes | 2 | 2014 | 26 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 137 | 0.060 |
Why?
|
| Nitriles | 2 | 2014 | 68 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2004 | 1085 | 0.060 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2003 | 31 | 0.060 |
Why?
|
| Imidazolidines | 1 | 2003 | 4 | 0.060 |
Why?
|
| Indoles | 1 | 2004 | 146 | 0.060 |
Why?
|
| Muscle, Skeletal | 2 | 2004 | 396 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 219 | 0.060 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 137 | 0.060 |
Why?
|
| Cloning, Molecular | 2 | 2014 | 357 | 0.060 |
Why?
|
| Pyroptosis | 1 | 2022 | 8 | 0.050 |
Why?
|
| Thiazepines | 1 | 2002 | 14 | 0.050 |
Why?
|
| Protein Binding | 2 | 2017 | 1027 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 212 | 0.050 |
Why?
|
| Pyridines | 3 | 2013 | 261 | 0.050 |
Why?
|
| B7-1 Antigen | 1 | 2021 | 20 | 0.050 |
Why?
|
| Lentivirus | 1 | 2021 | 35 | 0.050 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2002 | 67 | 0.050 |
Why?
|
| RAW 264.7 Cells | 1 | 2021 | 42 | 0.050 |
Why?
|
| Bradykinin | 1 | 2002 | 157 | 0.050 |
Why?
|
| Viral Envelope Proteins | 1 | 2021 | 43 | 0.050 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2021 | 28 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2021 | 144 | 0.050 |
Why?
|
| Estradiol | 1 | 2002 | 176 | 0.050 |
Why?
|
| Proteostasis | 1 | 2020 | 3 | 0.050 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2020 | 14 | 0.050 |
Why?
|
| Transient Receptor Potential Channels | 1 | 2020 | 5 | 0.050 |
Why?
|
| Sequestosome-1 Protein | 1 | 2020 | 12 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2020 | 63 | 0.050 |
Why?
|
| Nicotine | 1 | 2003 | 350 | 0.050 |
Why?
|
| Calcineurin Inhibitors | 1 | 2020 | 24 | 0.040 |
Why?
|
| Bortezomib | 1 | 2020 | 45 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 230 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2021 | 330 | 0.040 |
Why?
|
| Acute Disease | 1 | 2021 | 658 | 0.040 |
Why?
|
| Captopril | 1 | 2019 | 22 | 0.040 |
Why?
|
| Drug Synergism | 3 | 2004 | 260 | 0.040 |
Why?
|
| Young Adult | 1 | 2010 | 5710 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 370 | 0.040 |
Why?
|
| Colitis | 1 | 2020 | 156 | 0.040 |
Why?
|
| Apolipoproteins E | 2 | 2012 | 92 | 0.040 |
Why?
|
| Aged | 2 | 2013 | 14842 | 0.040 |
Why?
|
| alpha-Crystallin B Chain | 1 | 2017 | 1 | 0.040 |
Why?
|
| Cell Division | 3 | 2004 | 541 | 0.040 |
Why?
|
| Adolescent | 1 | 2010 | 8904 | 0.040 |
Why?
|
| Echocardiography | 1 | 2020 | 515 | 0.040 |
Why?
|
| Lung | 1 | 2021 | 849 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 567 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 24 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2017 | 614 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 1851 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2017 | 276 | 0.030 |
Why?
|
| Caspase 9 | 1 | 2014 | 31 | 0.030 |
Why?
|
| Receptors, Mating Factor | 1 | 2014 | 1 | 0.030 |
Why?
|
| 6-Aminonicotinamide | 1 | 2014 | 1 | 0.030 |
Why?
|
| HSC70 Heat-Shock Proteins | 1 | 2014 | 2 | 0.030 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Chloroquine | 1 | 2014 | 21 | 0.030 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2014 | 111 | 0.030 |
Why?
|
| Cadmium | 1 | 2014 | 21 | 0.030 |
Why?
|
| K562 Cells | 1 | 2014 | 44 | 0.030 |
Why?
|
| Tunica Intima | 2 | 2005 | 59 | 0.030 |
Why?
|
| Chromatography, Affinity | 1 | 2014 | 73 | 0.030 |
Why?
|
| Mutation | 2 | 2013 | 1213 | 0.030 |
Why?
|
| Receptors, IgE | 1 | 2014 | 22 | 0.030 |
Why?
|
| Valsartan | 2 | 2004 | 99 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 174 | 0.030 |
Why?
|
| Mitochondrial Uncoupling Proteins | 1 | 2013 | 1 | 0.030 |
Why?
|
| Zinc | 1 | 2014 | 73 | 0.030 |
Why?
|
| Adipose Tissue, White | 1 | 2013 | 7 | 0.030 |
Why?
|
| Adipose Tissue, Brown | 1 | 2013 | 8 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2014 | 233 | 0.030 |
Why?
|
| 3T3-L1 Cells | 1 | 2013 | 30 | 0.030 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2013 | 21 | 0.030 |
Why?
|
| Phosphorus | 1 | 2013 | 64 | 0.030 |
Why?
|
| Food Microbiology | 1 | 2013 | 24 | 0.030 |
Why?
|
| Fermentation | 1 | 2013 | 20 | 0.030 |
Why?
|
| Phosphates | 1 | 2013 | 72 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2014 | 204 | 0.030 |
Why?
|
| Deoxyglucose | 2 | 2004 | 32 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2013 | 144 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2004 | 18 | 0.030 |
Why?
|
| Glucose Transporter Type 4 | 2 | 2004 | 34 | 0.030 |
Why?
|
| Metformin | 1 | 2013 | 63 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2013 | 76 | 0.030 |
Why?
|
| Glycosylation | 1 | 2014 | 185 | 0.030 |
Why?
|
| Dietary Fats | 1 | 2013 | 103 | 0.030 |
Why?
|
| Monosaccharide Transport Proteins | 2 | 2004 | 54 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 284 | 0.030 |
Why?
|
| Serpin E2 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 81 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 2 | 2003 | 8 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2 | 2003 | 13 | 0.030 |
Why?
|
| Parathyroid Hormone | 1 | 2013 | 117 | 0.030 |
Why?
|
| Hot Temperature | 1 | 2013 | 152 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2014 | 172 | 0.030 |
Why?
|
| Protein Phosphatase 1 | 2 | 2003 | 36 | 0.030 |
Why?
|
| Heme Oxygenase-1 | 1 | 2013 | 40 | 0.030 |
Why?
|
| Copper | 1 | 2014 | 149 | 0.030 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2013 | 41 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2013 | 94 | 0.030 |
Why?
|
| Catalase | 1 | 2013 | 85 | 0.030 |
Why?
|
| Receptors, Angiotensin | 2 | 2003 | 59 | 0.030 |
Why?
|
| Zebrafish | 1 | 2013 | 187 | 0.030 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2013 | 76 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 137 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1070 | 0.030 |
Why?
|
| Myocarditis | 1 | 2012 | 49 | 0.030 |
Why?
|
| Aorta, Thoracic | 2 | 2005 | 211 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2014 | 238 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2004 | 648 | 0.030 |
Why?
|
| Hepcidins | 1 | 2012 | 6 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2013 | 149 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 706 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2014 | 1082 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2013 | 618 | 0.030 |
Why?
|
| Phosphoproteins | 2 | 2004 | 202 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 1446 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 209 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 361 | 0.020 |
Why?
|
| Mitochondria | 1 | 2015 | 643 | 0.020 |
Why?
|
| Blood Glucose | 2 | 2004 | 631 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2013 | 617 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 1037 | 0.020 |
Why?
|
| Potassium Chloride | 1 | 2007 | 45 | 0.020 |
Why?
|
| Carbachol | 1 | 2007 | 34 | 0.020 |
Why?
|
| Muscarinic Agonists | 1 | 2007 | 17 | 0.020 |
Why?
|
| Cell Shape | 1 | 2007 | 37 | 0.020 |
Why?
|
| Leucine | 1 | 2007 | 41 | 0.020 |
Why?
|
| Tritium | 1 | 2007 | 101 | 0.020 |
Why?
|
| Obesity | 1 | 2015 | 1074 | 0.020 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2007 | 26 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2007 | 28 | 0.020 |
Why?
|
| Carotid Artery Injuries | 1 | 2007 | 26 | 0.020 |
Why?
|
| Culture Media | 1 | 2007 | 155 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 2007 | 210 | 0.020 |
Why?
|
| Catheterization | 1 | 2007 | 209 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2007 | 102 | 0.020 |
Why?
|
| Carotid Stenosis | 1 | 2007 | 163 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2007 | 652 | 0.020 |
Why?
|
| Stress Fibers | 1 | 2005 | 10 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2005 | 19 | 0.020 |
Why?
|
| Focal Adhesions | 1 | 2005 | 25 | 0.020 |
Why?
|
| rho-Associated Kinases | 1 | 2005 | 32 | 0.020 |
Why?
|
| RNA Splicing | 1 | 2004 | 32 | 0.020 |
Why?
|
| Carotid Arteries | 1 | 2005 | 110 | 0.020 |
Why?
|
| CHO Cells | 1 | 2004 | 161 | 0.020 |
Why?
|
| Cricetinae | 1 | 2004 | 262 | 0.020 |
Why?
|
| Mice, Obese | 1 | 2004 | 33 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2007 | 493 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 2004 | 60 | 0.010 |
Why?
|
| Olmesartan Medoxomil | 1 | 2004 | 1 | 0.010 |
Why?
|
| Angiotensin II Type 2 Receptor Blockers | 1 | 2003 | 2 | 0.010 |
Why?
|
| Superoxides | 1 | 2004 | 70 | 0.010 |
Why?
|
| Rabbits | 1 | 2004 | 509 | 0.010 |
Why?
|
| Genes, fos | 1 | 2003 | 22 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2004 | 166 | 0.010 |
Why?
|
| Bradykinin Receptor Antagonists | 1 | 2003 | 20 | 0.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2003 | 23 | 0.010 |
Why?
|
| Cytosol | 1 | 2003 | 123 | 0.010 |
Why?
|
| Actins | 1 | 2005 | 249 | 0.010 |
Why?
|
| Mitosis | 1 | 2003 | 76 | 0.010 |
Why?
|
| Receptor, Bradykinin B2 | 1 | 2003 | 75 | 0.010 |
Why?
|
| Energy Intake | 1 | 2004 | 123 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2003 | 152 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 163 | 0.010 |
Why?
|
| DNA Replication | 1 | 2003 | 167 | 0.010 |
Why?
|
| Biological Transport | 1 | 2002 | 210 | 0.010 |
Why?
|
| Receptor Cross-Talk | 1 | 2002 | 16 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2002 | 19 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2002 | 63 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2002 | 142 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 289 | 0.010 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2002 | 155 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 1047 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 659 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2004 | 778 | 0.010 |
Why?
|